Market Research Report
Epiomic Epidemiology Series: Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027
|Published by||Black Swan Analysis||Product code||410909|
|Published||Content info||60 Pages
|Epiomic Epidemiology Series: Chronic Hepatitis C Forecast in 12 Major Markets 2017-2027|
|Published: January 1, 2017||Content info: 60 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Chronic Hepatitis C in 12 Major Markets
Hepatitis C is a single-stranded RNA virus that infects and damages the liver. In most cases, hepatitis C causes no noticeable symptoms until the liver has been significantly damaged. Symptoms are often vague such as flu-like muscle aches and fatigue.
This report provides the current prevalent population for Chronic Hepatitis C across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, Russia, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Chronic Hepatitis C have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Chronic hepatitis C is most often associated with co-infections with other chronic viral infections including:
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.